Stock listing
Hanover:KK3A Cytokinetics, Incorporated Aktie
German listing (Hanover) of Cytokinetics, Incorporated · home listing NASDAQ:CYTK
Follow Cytokinetics, Incorporated into a list and get an email when it puts out news.
Home listing price · NASDAQ:CYTK
$50.78 USD -0.54 (-1.1%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CYTK
- Day range
- $50.60 – $53.38 USDNov 20, 2026
- Volume
- 1.43M sharesNov 20, 2026
- Market cap
- $7.07B USDAt the close on Nov 20, 2026 · price × 139.3M shares outstanding
- 52-week range
- $50.60 – $88.31 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $129.5M USDMedian day 1.72M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CYTK · Home | $50.78 USD | -0.54 (-1.1%) | 1,426,568 | $51.23 | $53.38 | $50.60 | $51.32 | Close on Nov 20, 2026 |
| Frankfurt:KK3A | €45.69 EUR | -0.76 (-1.6%) | — | €46.06 | €46.06 | €45.69 | €46.45 | Close on Nov 20, 2026 |
| Munich:KK3A | €46.87 EUR | -1.10 (-2.3%) | — | €46.87 | €46.87 | €46.87 | €47.97 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CYTK · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $50.78 | -0.54 | -1.1% | $51.23 | $53.38 | $50.60 | 1,426,568 | |
| $51.32 | -0.33 | -0.6% | $51.30 | $52.84 | $51.04 | 1,594,452 | |
| $51.65 | -1.52 | -2.9% | $52.68 | $52.90 | $51.38 | 2,711,974 | |
| $53.17 | -2.96 | -5.3% | $55.39 | $55.62 | $52.68 | 1,754,721 | |
| $56.13 | -0.03 | -0.1% | $56.15 | $56.66 | $55.15 | 1,013,535 | |
| $56.16 | -2.37 | -4.0% | $58.30 | $58.58 | $55.67 | 2,008,636 | |
| $58.53 | +2.35 | +4.2% | $56.40 | $59.08 | $55.74 | 2,810,649 | |
| $56.18 | +1.04 | +1.9% | $54.67 | $57.21 | $54.12 | 2,357,528 | |
| $55.14 | +1.45 | +2.7% | $54.50 | $55.85 | $53.58 | 3,119,164 | |
| $53.69 | -1.86 | -3.3% | $55.70 | $56.51 | $53.55 | 2,560,975 | |
| $55.55 | -8.05 | -12.7% | $60.04 | $60.84 | $54.16 | 6,774,495 | |
| $63.60 | +1.29 | +2.1% | $64.06 | $64.95 | $60.98 | 2,686,320 | |
| $62.31 | +0.28 | +0.5% | $62.74 | $64.37 | $62.05 | 1,699,286 | |
| $62.03 | -0.96 | -1.5% | $63.40 | $64.00 | $61.97 | 1,559,905 | |
| $62.99 | -0.32 | -0.5% | $63.44 | $64.50 | $62.55 | 1,257,092 | |
| $63.31 | +2.03 | +3.3% | $62.08 | $63.92 | $61.54 | 1,425,387 | |
| $61.28 | -0.24 | -0.4% | $60.86 | $61.39 | $60.15 | 1,274,147 | |
| $61.52 | +0.79 | +1.3% | $60.68 | $61.82 | $60.47 | 1,147,815 | |
| $60.73 | -0.50 | -0.8% | $61.45 | $61.89 | $60.49 | 783,222 | |
| $61.23 | -1.10 | -1.8% | $62.01 | $62.44 | $60.89 | 985,434 | |
| $62.33 | -0.53 | -0.8% | $63.01 | $64.07 | $61.94 | 2,061,246 | |
| $62.86 | -1.09 | -1.7% | $64.30 | $64.78 | $62.46 | 1,080,574 | |
| $63.95 | +1.30 | +2.1% | $63.13 | $64.76 | $62.88 | 1,050,368 | |
| $62.65 | +0.70 | +1.1% | $62.06 | $63.61 | $61.84 | 1,912,775 | |
| $61.95 | -1.97 | -3.1% | $63.90 | $63.90 | $61.69 | 1,204,400 | |
| $63.92 | +0.49 | +0.8% | $64.81 | $65.57 | $63.81 | 1,665,100 | |
| $63.43 | +1.81 | +2.9% | $61.62 | $64.01 | $60.99 | 2,095,700 | |
| $61.62 | -1.17 | -1.9% | $62.32 | $63.05 | $61.50 | 1,936,000 | |
| $62.79 | -0.12 | -0.2% | $62.48 | $63.50 | $62.13 | 1,253,900 | |
| $62.91 | +0.90 | +1.5% | $61.87 | $63.03 | $61.59 | 1,118,500 | |
| $62.01 | +0.89 | +1.5% | $60.31 | $62.79 | $59.79 | 2,594,600 | |
| $61.12 | -0.23 | -0.4% | $61.09 | $62.05 | $60.15 | 2,395,600 | |
| $61.35 | -1.35 | -2.2% | $62.20 | $62.53 | $60.68 | 3,228,900 | |
| $62.70 | -2.90 | -4.4% | $65.60 | $65.76 | $62.19 | 3,234,300 | |
| $65.60 | -0.02 | 0.0% | $66.45 | $66.91 | $64.49 | 2,649,900 | |
| $65.62 | -0.29 | -0.4% | $65.73 | $67.27 | $65.30 | 1,724,300 | |
| $65.91 | +0.27 | +0.4% | $65.90 | $66.92 | $65.25 | 2,977,700 | |
| $65.64 | -0.52 | -0.8% | $65.91 | $66.52 | $64.38 | 2,401,400 | |
| $66.16 | +1.50 | +2.3% | $64.58 | $66.41 | $64.25 | 2,551,200 | |
| $64.66 | -1.00 | -1.5% | $65.66 | $65.95 | $64.44 | 1,599,200 | |
| $65.66 | -0.15 | -0.2% | $65.37 | $66.47 | $64.89 | 1,836,300 | |
| $65.81 | -1.78 | -2.6% | $67.02 | $67.39 | $64.73 | 2,050,900 | |
| $67.59 | +0.03 | 0.0% | $68.07 | $69.56 | $67.48 | 2,388,500 | |
| $67.56 | -1.22 | -1.8% | $69.30 | $69.50 | $67.35 | 1,603,400 | |
| $68.78 | -1.14 | -1.6% | $70.18 | $70.18 | $68.15 | 4,873,000 | |
| $69.92 | +0.53 | +0.8% | $70.64 | $71.05 | $68.92 | 1,398,200 | |
| $69.39 | +0.08 | +0.1% | $69.52 | $70.68 | $68.67 | 2,211,800 | |
| $69.31 | -3.14 | -4.3% | $72.13 | $72.19 | $68.55 | 2,576,600 | |
| $72.45 | -1.32 | -1.8% | $73.51 | $74.65 | $72.34 | 1,533,500 | |
| $73.77 | +0.15 | +0.2% | $74.66 | $75.98 | $73.50 | 1,721,500 | |
| $73.62 | -0.49 | -0.7% | $73.23 | $75.10 | $73.13 | 1,444,900 | |
| $74.11 | -1.24 | -1.6% | $74.31 | $74.89 | $73.52 | 1,424,800 | |
| $75.35 | +2.63 | +3.6% | $72.39 | $76.81 | $72.39 | 1,920,900 | |
| $72.72 | -1.23 | -1.7% | $73.04 | $74.01 | $72.26 | 1,140,900 | |
| $73.95 | +2.02 | +2.8% | $73.55 | $74.23 | $71.41 | 1,589,700 | |
| $71.93 | +0.53 | +0.7% | $71.90 | $73.70 | $70.42 | 1,605,700 | |
| $71.40 | +0.49 | +0.7% | $69.85 | $72.46 | $69.83 | 1,898,300 | |
| $70.91 | -1.18 | -1.6% | $71.54 | $71.79 | $69.31 | 3,078,100 | |
| $72.09 | -5.81 | -7.5% | $73.88 | $74.42 | $71.66 | 4,361,500 | |
| $77.90 | -1.30 | -1.6% | $78.84 | $79.13 | $77.84 | 1,109,800 | |
| $79.20 | +1.74 | +2.2% | $77.91 | $79.88 | $76.70 | 1,236,600 | |
| $77.46 | +0.37 | +0.5% | $77.93 | $78.72 | $77.21 | 1,260,832 | |
| $77.09 | +0.25 | +0.3% | $77.20 | $77.99 | $75.65 | 1,212,285 | |
| $76.84 | -0.34 | -0.4% | $77.30 | $77.70 | $76.65 | 1,521,300 | |
| $77.18 | -0.56 | -0.7% | $77.36 | $77.62 | $76.14 | 1,651,700 |
Splits
1 split · NASDAQ:CYTK · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-6 | Consolidation |
- Ticker
- Hanover:KK3A
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Hanover
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest earnings call · Nov 4, 2026
Cytokinetics (NASDAQ:CYTK) Q3 2026 Earnings Call
Replay and transcript
Latest deck · October 2026
HFSA Annual Scientific Meeting 2026
Conference · 12 slides
Latest news
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 16, 2026
Closed $51.65 (-2.9%) on Nov 17, 2026
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
Nov 16, 2026
Closed $53.17 (-5.3%) on Nov 16, 2026
Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
Nov 9, 2026
Closed $55.14 (+2.7%) on Nov 9, 2026
Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 4, 2026
Closed $55.55 (-12.7%) on Nov 5, 2026
Cytokinetics to Participate in November Investor Conferences
Nov 3, 2026
Closed $63.60 (+2.1%) on Nov 4, 2026
Cytokinetics to Announce Third Quarter Results on November 4, 2026
Oct 21, 2026
Closed $62.33 (-0.8%) on Oct 22, 2026
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Oct 19, 2026
Closed $62.65 (+1.1%) on Oct 19, 2026
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Oct 12, 2026
Closed $61.62 (-1.9%) on Oct 13, 2026
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Oct 2, 2026
Closed $65.60 (0.0%) on Oct 2, 2026
Cytokinetics, Incorporated on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 45 in the last 12 months · 299 in all · newest Nov 16, 2026 · oldest 2019
- Calls
- 26 calls with a replay · 26 with a transcript · latest Nov 4, 2026
- Decks
- 57 decks · latest October 2026
Where Cytokinetics, Incorporated is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CYTK · Home listing | NASDAQ | United States | USD |
| gettex:KK3A | gettex | Germany | EUR |
| LS Exchange:A1W1KK | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1W1KK | Lang & Schwarz | Germany | EUR |
| BOATS:CYTK | BOATS | United States | USD |
| Tradegate:KK3A | Tradegate | Germany | EUR |
| Milan:1CYTK | Milan | Italy | EUR |
| Frankfurt:KK3A | Frankfurt | Germany | EUR |
| BX Swiss:KK3A | BX Swiss | Switzerland | CHF |
| Dusseldorf:KK3A | Dusseldorf | Germany | EUR |
| Hamburg:KK3A | Hamburg | Germany | EUR |
| Munich:KK3A | Munich | Germany | EUR |
| Stuttgart:KK3A | Stuttgart | Germany | EUR |
| Hanover:KK3A · This page | Hanover | Germany | EUR |
| Xetra:KK3A | Xetra | Germany | EUR |
Valuation
EV/sales 56.2× against a median of 13.5×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $6.36B USD
- P/E
- Loss
- EV/sales
- 56.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 93.9%
- Operating margin
- −625.1%
- Net margin
- −686.6%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.93
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics, Incorporated · NASDAQ:CYTK | US$7.07B | US$6.36B | n/a | 56.2× | n/a | n/a | −686.6% | n/a | 0.93 |
| Summit Therapeutics Inc. · NASDAQ:SMMT | US$7.96B | US$7.33B | n/a | n/a | n/a | 14.1× | n/a | 0.0× | 1.91 |
| Protagonist Therapeutics, Inc. · NASDAQ:PTGX | US$7.92B | US$7.13B | 23.1× | 12.9× | 22.0× | 7.3× | 62.0% | 0.0× | 0.93 |
| Alkermes plc · NASDAQ:ALKS | US$7.55B | US$8.31B | n/a | 4.7× | 57.3× | 4.0× | −0.0% | 0.8× | 0.80 |
| CG Oncology, Inc. · NASDAQ:CGON | US$7.10B | US$6.12B | n/a | 992× | n/a | 7.2× | n/a | 0.0× | 0.83 |
| Axsome Therapeutics, Inc. · NASDAQ:AXSM | US$6.80B | US$6.68B | n/a | 7.7× | n/a | 64.5× | −18.2% | 1.8× | 0.69 |
| Akeso, Inc. · HKEX:9926 | US$6.66B | US$6.04B | n/a | 13.5× | n/a | 5.2× | −36.4% | 0.6× | n/a |
| Immunovant, Inc. · NASDAQ:IMVT | US$6.57B | US$5.85B | n/a | 825× | n/a | 10.0× | n/a | 0.0× | 1.46 |
| Oruka Therapeutics, Inc. · NASDAQ:ORKA | US$6.50B | US$5.58B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.30 |
| ImmunityBio, Inc. · NASDAQ:IBRX | US$6.40B | US$6.10B | n/a | 33.4× | n/a | n/a | −607.8% | n/a | 1.50 |
| Kodiak Sciences Inc · NASDAQ:KOD | US$6.35B | US$6.31B | n/a | n/a | n/a | 505× | n/a | 3.7× | 1.58 |
| Median of the others | US$6.73B | US$6.21B | 23.1× | 13.5× | 39.6× | 7.3× | −18.2% | 0.0× | 1.30 |
Forecasts
13 strong buy · 7 buy · 2 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 109.42 USD · Analysts' mean
- EPS, year to Dec 2026
- -5.76 · 17 analysts
- Revenue, year to Dec 2026
- 163.7M · 19 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Robert I. Blum | President and Chief Executive Officer |
| Sung Lee | EVP, Chief Financial Officer |
| Jeff Hessekiel | EVP, Chief Legal & Administrative Officer |
| John Faurescu | SVP, Deputy General Counsel & Corporate Secretary |
| Andrew Callos | EVP, Chief Commercial Officer |
| Diane Weiser | SVP, Corporate Affairs |
| Elisabeth A. Schnieders | SVP, Business Development |
| Fady I. Malik | EVP, Research & Development |
| Isaac Ciechanover | EVP, Corporate Development & Chief Business Officer |
| Stephen B. Heitner | SVP, Chief Medical Officer |
| Tricia Ottaviani | SVP, U.S. & Global Marketing and Operations |
Board
| Director | Role |
|---|---|
| John T. Henderson | Chairman |
| B. Lynne Parshall | Director |
| Edward M. Kaye | Director |
| Jim Daly | Director |
| Muna Bhanji | Director |
| Nancy J. Wysenski | Director |
| Robert A. Harrington | Director |
| Robert Landry | Director |
| Wendell Wierenga | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Cytokinetics (NASDAQ:CYTK) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 4:30 PM ET | Replay |
| Cytokinetics (NASDAQ:CYTK) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 4:30 PM ET | Replay |
| Cytokinetics (NASDAQ:CYTK) Q1 2026 Earnings Call | Tue, May 05, 2026 · 4:30 PM ET | Replay |
| Cytokinetics (NASDAQ:CYTK) Q4 2025 Earnings Call | Tue, Feb 24, 2026 · 4:30 PM ET | Replay |
| Cytokinetics (NASDAQ:CYTK) Q4 2026 Earnings Call | Tue, Feb 24, 2026 · 4:30 PM ET | Replay |
| Cytokinetics (NASDAQ:CYTK) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 4:30 PM ET | Replay |
| Cytokinetics (NASDAQ:CYTK) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Cytokinetics (NASDAQ:CYTK) Q1 2025 Earnings Call | Tue, May 06, 2025 · 4:30 PM ET | Replay |
| Cytokinetics (NASDAQ:CYTK) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 4:30 PM ET | Replay |
| Cytokinetics (NASDAQ:CYTK) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 4:30 PM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −12.7% |
| Q2 2026 | Aug 6, 2026 · After close | −5.7% |
| Q1 2026 | May 5, 2026 · After close | −2.9% |
| Q4 2025 | Feb 24, 2026 | −7.9% |
| Q3 2025 | Nov 5, 2025 · After close | +1.9% |
| Q2 2025 | Aug 7, 2025 · After close | −3.2% |
| Q1 2025 | May 6, 2025 · After close | −2.7% |
| Q4 2024 | Feb 25, 2025 · After close | +0.5% |
| Q3 2024 | Nov 6, 2024 · After close | +0.6% |
| Q2 2024 | Aug 8, 2024 · After close | +3.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −1.9% |
| Q4 2023 | Feb 27, 2024 · After close | −9.8% |
| Q3 2023 | Nov 2, 2023 · After close | +4.8% |
| Q2 2023 | Aug 2, 2023 · After close | +2.0% |
| Q1 2023 | May 4, 2023 · After close | +0.4% |
| Q4 2022 | Mar 1, 2023 · After close | −8.1% |
| Q3 2022 | Nov 3, 2022 · After close | −5.0% |
| Q2 2022 | Aug 4, 2022 · After close | +10.9% |
| Q1 2022 | May 4, 2022 · After close | −1.7% |
| Q4 2021 | Feb 24, 2022 · After close | +3.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| HFSA Annual Scientific Meeting 2026 | Conference | 12 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 70 slides | September 2026 |
| Technical Presentation (August 2026) | Technical | 20 slides | Aug 29, 2026 |
| Technical Presentation (August 2026) | Technical | 15 slides | Aug 29, 2026 |
| Investor Presentation (August 2026) | Investor deck | 65 slides | August 2026 |
| Technical Presentation (August 2026) | Technical | 23 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 63 slides | May 19, 2026 |
| Investor Presentation (May 2026) | Investor deck | 37 slides | May 5, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 29 slides | May 5, 2026 |
| Investor Presentation (March 2026) | Investor deck | 60 slides | March 2026 |
Show 50 decks
This page holds 50 of 57 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| 1.75% convertible senior notes due 2031 Made bigger: US$650M Use of proceeds: About $402.5M to exchange 2027 convertible notes; rest for aficamten launch and development, pipeline research and general corporate purposes | Sep 16, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88.0M | 18.5M | 7.53M | 94.6M | 70.4M | 55.8M | 26.9M | 31.5M | 13.4M | 106.4M |
| Cost of revenue | 10.1M | 339.4M | 330.1M | 240.8M | 159.9M | 97.0M | 86.1M | 89.1M | 90.3M | 59.9M |
| Gross profit | 77.9M | -320.9M | -322.6M | -146.2M | -89.5M | -41.1M | -59.3M | -57.6M | -76.9M | 46.5M |
| Research and development | 416.0M | 339.4M | 330.1M | 240.8M | 159.9M | 97.0M | 86.1M | 89.1M | 90.3M | 59.9M |
| Selling, general and administrative | 284.3M | 215.3M | 173.6M | 178.0M | 96.8M | 52.8M | 39.6M | 31.3M | 36.5M | 27.8M |
| Operating income | -612.3M | -536.2M | -496.2M | -324.2M | -186.3M | -93.9M | -98.9M | -88.9M | -113.4M | 18.7M |
| Depreciation and amortization | 10.1M | 9.53M | 11.9M | 5.81M | 2.28M | 1.83M | 1.29M | 1.24M | 1.92M | 741.0K |
| EBITDA | -602.1M | -526.7M | -484.3M | -318.4M | -184.0M | -92.1M | -97.6M | -87.7M | -111.5M | 19.4M |
| Interest expense | 45.6M | 37.7M | 28.3M | 19.4M | 16.4M | 16.0M | 6.62M | 3.80M | 3.02M | 2.70M |
| Income before tax | -785.0M | -589.5M | -526.2M | -389.0M | -215.3M | -127.3M | -121.7M | -106.3M | -127.8M | 16.5M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -785.0M | -589.5M | -526.2M | -389.0M | -215.3M | -127.3M | -121.7M | -106.3M | -127.8M | 16.5M |
| Earnings per share, basic | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 | -1.97 | -2.11 | -1.95 | -2.59 | 0.41 |
| Earnings per share, diluted | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 | -1.97 | -2.11 | -1.95 | -2.59 | 0.39 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 122.5M | 94.9M | 113.0M | 65.6M | 112.7M | 83.0M | 36.4M | 42.3M | 125.2M | 66.9M |
| Short-term investments | 759.7M | 981.2M | 501.8M | 717.0M | 359.0M | 381.1M | 188.7M | 156.5M | 143.7M | 89.4M |
| Receivables | 17.8M | 16.6M | 1.28M | 147.0K | 51.8M | 4.42M | 5.16M | 2.23M | 1.11M | 24.0K |
| Inventory | 0 | -11.9M | -147.0K | -51.8M | -4.42M | -6.79M | 1 | 0 | ||
| Current assets | 917.0M | 1.11B | 628.1M | 795.2M | 535.7M | 474.2M | 233.8M | 207.7M | 274.3M | 158.6M |
| Property, plant and equipment | 79.2M | 65.8M | 68.7M | 80.5M | 73.3M | 13.3M | 4.53M | 3.20M | 3.57M | 3.64M |
| Goodwill | 0 | 0 | 0 | |||||||
| Total assets | 1.42B | 1.40B | 824.3M | 1.01B | 841.3M | 533.8M | 289.8M | 211.2M | 294.8M | 170.1M |
| Accounts payable | 22.3M | 20.4M | 21.5M | 25.6M | 21.1M | 8.05M | 8.16M | 3.76M | 5.25M | 4.24M |
| Current liabilities | 202.5M | 179.7M | 102.7M | 84.6M | 71.9M | 31.2M | 26.0M | 22.2M | 32.4M | 33.3M |
| Long-term debt | 246.4M | 93.2M | 58.4M | 63.8M | 47.4M | 46.2M | 45.1M | 39.8M | 31.8M | 27.4M |
| Total debt | 287.6M | 619.5M | 639.3M | 649.6M | 47.4M | 46.2M | 45.1M | 42.4M | 31.8M | 29.9M |
| Total liabilities | 2.08B | 1.54B | 1.21B | 1.12B | 597.5M | 420.4M | 300.8M | 185.2M | 185.0M | 75.8M |
| Shareholders' equity | -659.6M | -135.4M | -386.3M | -107.9M | 243.9M | 113.4M | -10.9M | 25.9M | 109.8M | 94.4M |
| Shares outstanding | 122.9M | 118.2M | 101.6M | 94.8M | 84.8M | 71.0M | 59.2M | 54.7M | 54.0M | 40.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -510.0M | -395.9M | -414.3M | -299.5M | -142.5M | 8.94M | -90.9M | -101.2M | -101.8M | 37.0M |
| Capital spending | -24.8M | -3.91M | -1.42M | -11.3M | -48.9M | -11.1M | -2.62M | -889.0K | -2.88M | -1.60M |
| Free cash flow | -534.8M | -399.8M | -415.7M | -310.9M | -191.4M | -2.11M | -93.5M | -102.1M | -104.6M | 35.4M |
| Cash from investing | 16.7M | -553.1M | 239.3M | -262.1M | -147.8M | -196.5M | -74.7M | 5.13M | -65.8M | -52.1M |
| Cash from financing | 524.5M | 930.6M | 221.3M | 516.2M | 320.0M | 234.1M | 159.8M | 13.1M | 225.9M | 16.9M |
| Dividends paid | -18.5M | 0 | 0 | 0 | ||||||
| Share buybacks | 53.0M | -10.5M | 17.5M | -4.45M | -2.25M | 37.6M | 3.23M | 126.5M | 1.90M | |
| Change in cash | 30.4M | -18.2M | 46.2M | -45.5M | 29.7M | 46.6M | -5.82M | -83.0M | 58.3M | 1.80M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 28, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 27, 2026 | Offer document | SEC |
| 8-K · Current report | May 27, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 8-K · Current report | May 8, 2026 | Current report | SEC |
| 424B5 · Prospectus | May 7, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | May 5, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 8-K · Current report | May 5, 2026 | Current report | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 17, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 24, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 17, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 19, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
This page holds 200 of 1,002 filings. Open Filings
Cap table
Built by 6ix from Cytokinetics, Incorporated’s releases · as of Nov 13, 2026
- Common shares
- 139,303,351
- Fully diluted
- 139,409,957
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 139,303,351 | Nov 2, 2026 |
| Options and RSUs | 106,606 | Nov 13, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · US$56.13 · expire about Nov 2036 |
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 139,303,351 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Wendall Wierenga Other companies: Crinetics Pharmaceuticals, Inc. (Director · Since at least Jul 17, 2018); Concert Pharmaceuticals Inc (Director · Mar 13, 2014 – Jun 14, 2018 · Past); Apricus Biosciences Inc (Director · Mar 10, 2014 – Jan 4, 2018 · Past); Ocera Therapeutics Inc (Director · Dec 19, 2013 – Dec 11, 2017 · Past); Santarus Inc (EVP, R&D · Jun 20, 2011 – Jan 2, 2014 · Past); XenoPort Inc (Director · May 7, 2009 – Jul 5, 2016 · Past); Onyx Pharmaceuticals Inc (Director · Dec 15, 2008 – Oct 1, 2013 · Past) | Director · Since at least Feb 9, 2011 |
| Lynne Parshall Other companies: Foghorn Therapeutics Inc. (Director, Ionis Pharmaceuticals · Since at least Aug 16, 2022); Ionis Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2006); Akcea Therapeutics Inc (Director · Jul 13, 2017 – Oct 12, 2020 · Past); Regulus Therapeutics Inc (Director · Oct 4, 2012 – Nov 3, 2014 · Past); Cardiodynamics International Corp (Director · Jul 20, 2006 – Aug 14, 2009 · Past) | Director · Since at least Feb 7, 2013 |
| Santo J Costa Other companies: Aquestive Therapeutics, Inc. (Director · Jul 24, 2018 – Jun 20, 2024 · Past); Osi Pharmaceuticals Inc (Director · Jun 14, 2006 – Jun 7, 2010 · Past); CV Therapeutics Inc (Director · Jun 6, 2006 – Apr 14, 2009 · Past); NPS Pharmaceuticals Inc (Director · Jan 17, 2006 – May 22, 2007 · Past) | Director · Nov 1, 2010 – May 15, 2024 · Past |
| Edward M. Kaye Other companies: Avidity Biosciences, Inc (Director · Since at least Jun 11, 2020); Stoke Therapeutics, Inc. (Director · Since at least Jun 18, 2019); Sarepta Therapeutics, Inc. (Chair of Scientific Advisory Board · Apr 24, 2012 – Nov 4, 2026 · Past) | Director · Since at least May 18, 2016 |
| James Daly Other companies: Halozyme Therapeutics, Inc. (Director · Since Sep 30, 2026); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 20, 2025); ACADIA Pharmaceuticals Inc. (Director · Since at least May 29, 2025) | Director · Since at least Aug 19, 2025 |
| Muna Bhanji Other companies: Intellia Therapeutics, Inc. (Independent Director · Since at least Apr 28, 2022); Veracyte, Inc. (Director · Since at least Mar 19, 2021); Ardelyx, Inc. (Director · Since at least Mar 11, 2021) | Director · Since at least Feb 17, 2021 |
| Robert E. Landry Other companies: Theravance Biopharma, Inc. (Director · Since at least Nov 5, 2026); Zymeworks Inc. (Director · Since at least Aug 10, 2025); Regeneron Pharmaceuticals, Inc. (EVP Finance CFO · Mar 31, 2022 – Feb 2, 2024 · Past) | Director · Since at least Feb 10, 2025 |
| Sung Lee Other companies: Tango Therapeutics, Inc. (Executive Vice President and Chief Financial Officer, Cytokinetics · Since at least Jan 2, 2026); Vir Biotechnology, Inc. (EVP & Chief Financial Officer · Mar 27, 2023 – Mar 27, 2024 · Past); Sangamo Therapeutics, Inc. (EVP, Chief Financial Officer · Oct 31, 2019 – Nov 25, 2020 · Past) | EVP, Chief Financial Officer · Since at least Apr 26, 2024 |
| Caryn Gordon McDowell Other companies: Quince Therapeutics, Inc. (Chief Legal & Adm. Officer · May 5, 2020 – Jun 6, 2022 · Past); Revance Therapeutics, Inc. (SVP, GC & Secretary · May 1, 2018 – Feb 15, 2020 · Past) | GC & Chief Compliance Officer · May 18, 2016 – Feb 27, 2018 · Past |
| Peter S Roddy Other companies: Filana Therapeutics, Inc. (Chief Financial Officer · May 1, 2010 – Apr 8, 2016 · Past); Aspira Women's Health Inc. (Director · Feb 18, 2010 – Mar 17, 2016 · Past) | SVP Finance & CAO · Feb 8, 2018 – Feb 27, 2018 · Past |
All 32 people
| Person | Seat |
|---|---|
| Wendell Wierenga Other companies: Crinetics Pharmaceuticals, Inc. (Director · Since at least Jun 18, 2026); Dermata Therapeutics, Inc. (Director · Since at least Aug 12, 2021) | Director · Since at least Oct 15, 2025 |
| Bonnie Charpentier Other companies: Genitope Corp (VP of Regulatory Affairs · Dec 31, 2005 – Apr 27, 2006 · Past) | SVP Regulatory & Compliance · Jan 2, 2014 – Feb 28, 2017 · Past |
| Brett A Pletcher Other companies: Gilead Sciences, Inc. (EVP,Corp Affairs & Gen Counsel · May 9, 2018 – Jun 10, 2022 · Past) | EVP, Chief Legal Officer · Aug 13, 2024 – Aug 30, 2024 · Past |
| Fady I. Malik Other companies: Rocket Pharmaceuticals, Inc. (Independent Director · Since at least Mar 10, 2022) | EVP, Research & Development · Since at least Jun 1, 2012 |
| Jeff Hessekiel Other companies: Exelixis, Inc. (EVP & General Counsel · May 15, 2025 – May 15, 2025 · Past) | Chief Legal & Admin Officer · Since at least Nov 13, 2025 |
| Mark A Schlossberg Other companies: Impax Laboratories Inc (SVP and General Counsel · Feb 26, 2018 – May 4, 2018 · Past) | SVP - Legal & General Counsel · Jan 14, 2019 – Mar 15, 2022 · Past |
| Michael Rabson Other companies: Maxygen Inc (Senior Vice President · Jan 3, 2006 – Feb 1, 2008 · Past) | SVP Business Dev/Legal & GC · Mar 31, 2008 – Dec 18, 2009 · Past |
| Andrew Callos | EVP, Chief Commercial Officer · Since at least Mar 15, 2021 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev · Nov 16, 2015 – Aug 31, 2017 · Past |
| Ching Jaw | SVP Finance & CFO · Jun 26, 2017 – Mar 6, 2023 · Past |
| Diane Weiser | SVP, Corporate Affairs · Since at least Nov 3, 2026 |
| Elisabeth A. Schnieders | SVP, Business Development · Since at least Nov 5, 2026 |
| Isaac Ciechanover | EVP, Corporate Development & Chief Business Officer · Since at least Nov 5, 2026 |
| John Faurescu | SVP, Deputy General Counsel & Corporate Secretary · Since at least Nov 5, 2026 |
| John T. Henderson | Director · Since at least Apr 15, 2025 |
| Nancy J. Wysenski | Director · Since at least Apr 15, 2026 |
| Robert A. Harrington | Director · Since at least Apr 8, 2022 |
| Robert I. Blum | President & CEO, Director · Since at least Apr 1, 2026 |
| Robert Wong | VP, Chief Accounting Officer · May 15, 2019 – Dec 3, 2024 · Past |
| Sandford D Smith | Director · Apr 1, 2022 – Jan 2, 2024 · Past |
| Stephen B. Heitner | SVP, Chief Medical Officer · Since at least Oct 12, 2026 |
| Tricia Ottaviani | SVP, U.S. & Global Marketing and Operations · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Cytokinetics, Incorporated.